GreenLight Biosciences Gross Profit

The latest gross profit for GRNA is $10M as of March 2023. That compares with $260K in the prior-year period — up 3870.4% year over year. That is below the sector sector average of $760M. Investors often review this figure alongside GreenLight Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, GRNA's gross profit moved from $260K to $10M — a 3870.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GreenLight Biosciences's operating scale or balance-sheet position.

Against its sector companies, GRNA currently prints $10M for gross profit, while the sector average sits near $760M. That is roughly 98.7% below the sector mean. Large gaps often invite a closer look at GreenLight Biosciences's growth, margins, and balance sheet.

A gross profit figure of $10M for GRNA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $760M. Explore the charts below for those layers of context.

After noting GRNA's gross profit ($10M), review year-over-year change from $260K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.